Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
| Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Acute trial of rimegepant for treatment of migraine - patient questionnaire | Migraine - treating | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Alemtuzumab | Highly active relapsing remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Amantadine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Amifampridine | Lambert-Eaton myasthenic syndrome (NHSE) | Double Red | n/a | Hertfordshire and West Essex ICB |
| Anticholinergic burden (ACB) | Structured medication review Eclipse Live | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Anticholinergic burden (ACB) | Structured medication review Hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Apomorphine | Parkinson's disease | Red | Decision document | Hertfordshire and West Essex ICB |
| Atogepant | Migraine - prevention | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Attention deficit hyperactivity disorder (ADHD) | FAQs | n/a | Primary Care prescribing resource | South and West Hertfordshire |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol | Amber protocol | Shared care protocol | West Essex |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol - children, young people and adults | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Bobath Therapy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Cannabis-based medicinal preparations | Intractable nausea & vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy | Red | Position statement | Hertfordshire and West Essex ICB |
| Carbamazepine | Epilepsy | Green | n/a | Hertfordshire and West Essex ICB |
| Cenobamate | Focal onset seizures | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cladribine | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Clomipramine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Clonazepam | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Co-beneldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Co-careldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Co-careldopa (Carbidopa/levodopa) intestinal gel | Parkinson's disease (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Co-careldopa Intestinal Gel (Duodopa) | Parkinson's Disease (NHSE tertiary centre only) | Red | n/a | Hertfordshire and West Essex ICB |
| Co-proxamol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Cytisine | Smoking cessation | Double Red | n/a | Hertfordshire and West Essex ICB |
| Daridorexant | Insomnia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Daridorexant | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
| Daridorexant | Long-term insomnia | Green | Prescribing support document | Hertfordshire and West Essex ICB |
| Dependence forming medicine | Pain - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Dexamfetamine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Domperidone | Nausea vomiting in children | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Donepezil | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Drug Titration and Review for Neuropathic Pain | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Electronic Cigarettes and other novel nicotine containing products | Tobacco dependance | Red | Position statement | Hertfordshire and West Essex ICB |
| Entacapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Epilepsy, Fits and Seizures | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Eptinezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Eptinezumab | Migraine - episodic | Red | Decision document | Hertfordshire and West Essex ICB |
| Erenumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Erenumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ethosuximide | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Ethosuximide capsules | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Ethosuximide syrup | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Fampridine | Multiple sclerosis (NHSE) | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Fentanyl immediate release (IR) | Pain (except for palliative care) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Fingolimod | Highly active relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fremanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Fremanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Gabapentin | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Galantamine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Galcanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Galcanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB, East and North Hertfordshire, South and West Hertfordshire, West Essex |
| Glatiramer | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Glycopyrronium bromide oral | Hypersalivation | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Headache | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Lacosamide | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Lamotrigine | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Levetiracetam | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Long term insomnia management | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
| Mechanical Insufflation-Exsufflation (MI-E) Devices / CoughAssist | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Melatonin | Insomnia - Neurodevelopmental Disorders in patients under the age of 18 years | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - Learning disability in adults and paediatrics | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - product options in neurodevelopmental disorders in patients aged 2 to under 18 years | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - product options in adult and paediatric patients with learning disabilities | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia adults excluding learning disabilities | Double Red | n/a | Hertfordshire and West Essex ICB |
| Melatonin (Slenyto) | Insomnia | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Memantine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Methylphenidate | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Mexiletine | Myotonia in non-dystrophic myotonic disorders (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Midazolam (Buccolam) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Midazolam (Epistatus) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Migraine | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Migraine | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Migraine with or without Aura | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Modafinil | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Motor Neurone Disease (MND) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Multiple Sclerosis (MS) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Natalizumab | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Neuropathic Pain Drug Titration and Review | n/a | Clinical pathways | East and North Hertfordshire | |
| Nitrazepam | Insomnia | Double Red | n/a | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Open MRI | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Open Mri Prior Approval Form | n/a | Prior approval form | Hertfordshire and West Essex ICB | |
| Opicapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Opioid | Pain - long-term prescribing for non-cancer, chronic pain in adults | Double Red | Position statement | Hertfordshire and West Essex ICB |
| Opioid | Pain - persistent self care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Opioid | Pain - plan agreement | n/a | Patient information | Hertfordshire and West Essex ICB |
| Opioid | Pain - review letter | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Opioid Aware Campaign | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
| Opioid Prescribing Position Statement | Pain | n/a | Position statement | Hertfordshire and West Essex ICB |
| Opioid reduction | Opioid reduction tool | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Orphenadrine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Oxcarbazepine | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Oxycodone and naloxone | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paracetamol and tramadol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Peginterferon | All indication | Red | Decision document | Hertfordshire and West Essex ICB |
| Pentosan polysulfate sodium | Bladder pain syndrome | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Phenobarbital | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Phenytoin | Epilepsy | Green | n/a | Hertfordshire and West Essex ICB |
| Pitolisant | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Pramipexole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
| Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
| Primidone | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Procyclidine | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
| Promethazine | All indications | n/a | Position statement | Hertfordshire and West Essex ICB |
| Rapid Onset Isolated Visual Loss (No other neurological symptoms or signs) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Rasagiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Riluzole | Amyotrophic Lateral Sclerosis (ALS) form of Motor Neurone Disease (MND) | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine - prevention | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine - treating | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivastigmine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Ropinirole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Rotigotine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Selective serotonin reuptake inhibitors (SSRIs) | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Selegiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Shared care | Attention deficit hyperactivity disorder (ADHD) by Private Provider | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Siponimod | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Sodium oxybate | Narcolepsy with cataplexy (tertiary centre only) | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Solriamfetol | Excessive daytime sleepiness caused by narcolepsy (tertiary centre only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Solriamfetol apnoea | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Spinal Cord Stimulation | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Stroke | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Tapentadol IR | Pain - acute moderate to severe | Double Red | n/a | Hertfordshire and West Essex ICB |
| Teriflunomide | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| TIA (Transient Ischemic Attack) | n/a | Clinical pathways | East and North Hertfordshire | |
| Topiramate | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Transcranial Magnetic Stimulation (TMS and rTMS) | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Tremor in Primary Care |Initial Assessment | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Trihexyphenidyl (Benzhexol) | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
| Trimipramine - stopping and switching guidance | Depression | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Venlafaxine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Vigabatrin | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |